MaxCyte Inc (MXCT)
Healthcare
Medical Devices
1.10 $
+0.0%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns MaxCyte Inc (MXCT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 91.1% of the shares are freely tradable; institutional investors hold 68.0%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
68.0%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
1.5%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
91.1%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
4.0%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
107Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 8.21 | 8,798,473 | -4.8 | 03/31/2026 |
| Capricorn Fund Managers Ltd | 7.65 | 8,200,000 | +0.0 | 03/31/2026 |
| Vanguard Group Inc | 5.17 | 5,539,260 | -0.9 | 12/31/2025 |
| Vitruvian Partners | 4.71 | 5,043,356 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.72 | 3,981,816 | +0.0 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 3.44 | 3,688,131 | -16.8 | 03/31/2026 |
| Mudita Advisors LLP | 3.15 | 3,370,689 | +0.0 | 03/31/2026 |
| BNP Paribas Investment Partners SA | 2.59 | 2,773,554 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| RGI UK Listed Smaller Coms B Acc | 3.55 | 3,800,000 | +15.2 | 05/31/2026 |
| AXA Framlington Health Fund - R Income | 2.59 | 2,773,554 | +0.0 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.